China accepts CANbridge's NDA for CAN108 to treat cholestati

The National Medical Products Administration (NMPA) of China has accepted the new drug application (NDA) submitted by CANbridge Pharmaceuticals for CAN108.

Related Keywords

China , Taiwan , Canada , Hong Kong , James Xue , Mirum Pharmaceuticals , Canbridge Pharmaceuticals , Drug Administration ,